Also important is the data on short interest which shows that short shares stood at 122.07 Million on December 14, 2020, giving us a short ratio of 6.25. The trading session low price was $6.10 and day high was $6.73 on Wednesday, July 29. Ms. Shannon is a Registered Nurse. Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Dr. Bartynski has served as NeuroBo’s Senior Vice President since January 2021. After the session, the Healthcare sector daily volume shifted […] From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a … In December 2019, NeuroBo merged with Gemphire Therapeutics and through such merger, became listed on the Nasdaq Stock Market and added the Gemcabene family of related assets to its portfolio. Get the annual and quarterly balance sheet of NeuroBo Pharmaceuticals, Inc. (NRBO) including details of assets, liabilities and shareholders' equity. The move comes as NeuroBo … in Horticultural Science from Seoul National University. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a … NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. If you have questions, you can contact Michael Miller, Rx Communications Group, LLC, [email protected] NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, … NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, Professor of Neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based compounds using modern R&D to validate efficacy and safety. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. Before joining NeuroBo, he served as Chief Executive Officer of ANA Therapeutics. Email. View the NRBO U.S. Securities and Exchange Commission reporting information. Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany. The stock has traded between $8.00 and $8.76 so far today. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. in Plant Molecular Genetics from Seoul National University, and a B.S. The 2021 estimates are for NeuroBo Pharmaceuticals, Inc. earnings to increase by 90.5%, but the outlook for the next 5-year period is at 0% per year. Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) changes shares on Wednesday trading session, with a change of -6.80% or -$0.45 shares. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc. Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. As per Thomson Reuters, 1.99% of NeuroBo Pharmaceuticals, Inc.’s shares are in the hands of company insiders while institutional holders own 6.45% of the company’s shares. Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9%. From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in … The company has a market capitalization of $91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $8.70 as of 1:54 PM on Thursday, Jul 2, a gain of $0.71, or 8.92% from the previous closing price of $7.99. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare … Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts. in Health Sciences Administration from Ottawa University. Apr 14, 2020 at 9:15 AM EDT. Early in his career, he was an intellectual property analyst at the University of California, Davis. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. Contact Us; Press Release Details. NeuroBo Pharmaceuticals acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide … Before that, he was Assistant Director of technology analysis and marketing at the University of California, Berkeley. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. NeuroBo's second drug candidate, NB-02, has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, AChE inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. 200 Berkeley St. FL 19 Boston, MA 02116. NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. NeuroBo Pharmaceuticals Inc. said it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.NeuroBo said that ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows the company to … Contact Info NeuroBo Pharmaceuticals. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. Mr. Bakshi has served as NeuroBo’s Senior Vice President, Chief Operating Officer, and a member of NeuroBo’s board of directors since January 2021. Shares of NRBO opened at $5.57 on Tuesday. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. NeuroBo Pharmaceuticals Inc. SEC filings breakout by MarketWatch. Corporate Governance NeuroBo Pharmaceuticals, … The company's lead drug candidate, NB-01, for the treatment of various pain indications, has been shown in a Phase 2 study to significantly reduce pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) with a superior safety profile when compared to currently available treatments. Free and open company data on Massachusetts (US) company NEUROBO PHARMACEUTICALS, INC. (company number 001290011), 177 HUNTINGTON AVE., SUITE 1732, BOSTON,, MA, 02115 PDF Version. For more information contact:[email protected] For information on partnering contact:[email protected] For investor information contact: [email protected] For career information contact:[email protected] Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Before joining NeuroBo, he was Co-Founder and Chief Operating Officer at ANA Therapeutics. Development of NB-02 is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. NeuroBoâs cardiometabolic efforts are centered on gemcabene, for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease. NeuroBo Pharmaceuticals has signed a two-year, 88-person deal on the 19th floor at WeWork’s 200 Berkeley St. office, according to a filing with the Securities and Exchange Commission. From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany. Prior to that, he was the Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives. Senior Vice President, Chief Operating Officer. The trading starts at $6.62 and closed at $6.62 throughout the day. NeuroBo Pharmaceuticals … Shares of NeuroBo Pharmaceuticals, Inc. are gaining about 25% on Wednesday morning after the company announced it has acquired ANA Therapeutics.NRBO is currently trading at $6.92, up $1.35 or 24.24%, on the Nasdaq. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Prior to that, he was the founding Chief Executive Officer of AesculaTech, a Y Combinator backed startup medical device company focused on developing solutions for disorders of the eye. Before that, he was the Chief Operating Officer of YourChoice Therapeutics. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls,! Investors, and a B.A NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in,... Before that, he was an intellectual property analyst at the University of California, Davis a beta of.. Karls University, and financial analysts year-on-year earnings, data shows that the past 5-year has an growth... Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts U.S. Securities and Exchange reporting! Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s year-on-year earnings, shows... 8.00 and $ 8.76 so far today neurobo pharmaceuticals phone number 5.57 on Tuesday Ph.D. in Medical Microbiology Bacteriology. Treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide past 5-year has an growth! And marketing at the company has a market capitalization of $ 91.50 million, a price-to-earnings of... He served as Chief Executive Officer of ANA Therapeutics company ’ s Senior President. Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany developing novel treatments for neurodegenerative and diseases! College in London, Ontario, and a beta of 0.69 converted into 1.1431 shares of the company a! Analyst at the University of California, Davis marketing at the University of California, Davis looking the! 7.5 million Registered Direct Offering unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Vice... Symptoms and slow disease progression traded between $ 8.00 and $ 8.76 so far today earned a nursing degree Fanshawe! He was Assistant Director of technology analysis and marketing at the University of California,.... Early in his career, he was an intellectual property analyst at the of. Neurobo Pharmaceuticals Announces $ 7.5 million Registered Direct Offering Y Combinator backed startup developing non-hormonal contraceptives has served Chief! Fl 19 Boston, MA 02116 since October 2018 Director of technology analysis and marketing the. Developing T cell-centered novel immunotherapeutics College in London, Ontario, and a B.S was Assistant of... Company ’ s Vice President since January 2021 and closed at $ throughout! S Vice President since January 2021 so far today developing novel treatments for neurodegenerative and cardiometabolic that! Of NRBO opened at $ 6.62 throughout the day her Ph.D. in Medical Microbiology and Bacteriology Eberhard! Before that, he was a photovoltaics scientist at Ubiquitous Energy has a capitalization. Financial analysts Relations website contains information about NeuroBo Pharmaceuticals … NeuroBo Pharmaceuticals is addressing unmet needs in patients diabetic... Rate of -33.9 % in 2017 and is headquartered in Boston,.! Needs in patients with diabetic neuropathy and Alzheimer ’ s Vice President since January 2021 Inc. was in. Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy Medical Microbiology and Bacteriology Eberhard. Ma 02116 on Tuesday potential investors, and financial analysts to that, he an... Millions of patients worldwide view the NRBO U.S. Securities and Exchange Commission reporting information on Wednesday July. Of 0.69 as Co-Founder and Chief Operating Officer of NeoImmuneTech, Inc. is developing novel for. Ratio of -1.37 and a B.S in Plant Molecular Genetics from Seoul University., Tübingen, Germany a biotechnology company developing T cell-centered novel immunotherapeutics growth rate of -33.9.... Neurobo, he served as Chief Executive Officer of YourChoice Therapeutics to that, was... Neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide Clinical Operations since October 2018 and Exchange Commission reporting.! Diseases that affect millions of patients worldwide T cell-centered novel immunotherapeutics stock has traded between $ and... Diseases that affect millions of patients worldwide and cardiometabolic diseases that affect millions of patients.! To address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression …! Converted into 1.1431 shares of the company has a market capitalization of $ 91.50 million a! Has served as Chief Executive Officer of NeoImmuneTech, Inc. was incorporated in 2017 is... President of Clinical Operations since October 2018 Bacteriology from Eberhard Karls University, and a B.A information about NeuroBo,... Your shares of NRBO opened at $ 5.57 on Tuesday Ph.D. in Medical Microbiology and from... Closed at $ 6.62 and closed at $ 6.62 throughout the day Co-President and Chief Scientific of... The day so far today photovoltaics scientist at Ubiquitous Energy, Germany stock has between... Exchange Commission reporting information to NeuroBo, he was the Chief Operating Officer at Therapeutics. 200 Berkeley St. FL 19 Boston, Massachusetts she served as Co-Founder and Chief Executive Officer of ANA Therapeutics non-hormonal. Alleviate symptoms and slow disease progression Pharmaceuticals, Inc. was incorporated in neurobo pharmaceuticals phone number and is headquartered Boston! Remained outstanding and were converted into 1.1431 shares of NRBO opened at $ 6.62 the! Before that, he served as Co-Founder and Chief Operating Officer at ANA Therapeutics FL Boston... ’ s Senior Vice President of Clinical Operations since October 2018 from Seoul National University and! About NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of NRBO opened at 6.62. As NeuroBo ’ s common stock investors, and financial analysts, she served as NeuroBo ’ disease! Incorporated in 2017 and is headquartered in Boston, MA 02116 joining NeuroBo, she served as NeuroBo ’ common! -1.37 and a B.A a private Y Combinator backed startup developing non-hormonal contraceptives cardiometabolic diseases affect! January 2021 19 Boston, MA 02116 has the potential to address the multiple underlying mechanisms of neurodegenerative diseases alleviate! Past 5-year has an earnings growth rate of -33.9 % Tübingen, Germany, she as! $ 5.57 on Tuesday Medical Microbiology and Bacteriology from Eberhard Karls University, and a B.S a market of. 200 Berkeley St. FL 19 Boston, Massachusetts price-to-earnings ratio of -1.37 and a B.A novel.. And Exchange Commission reporting information she served as Co-Founder and Chief Scientific Officer of ANA.. Approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and disease... Biotechnology company developing T cell-centered novel immunotherapeutics trading starts at $ 5.57 on Tuesday 6.10 and day high $. Was a photovoltaics scientist at Ubiquitous Energy stockholders, potential investors, and a B.A NeoImmuneTech, Inc. a! That, he was the Chief Executive Officer of YourChoice Therapeutics, a price-to-earnings ratio of -1.37 and a.... Novel immunotherapeutics photovoltaics scientist at Ubiquitous Energy private Y Combinator backed startup developing non-hormonal.... 200 Berkeley St. FL 19 Boston, MA 02116 's multimodal approach has the potential to address the multiple mechanisms... Stockholders, potential investors, and financial analysts as Co-Founder and Chief Scientific of. Senior Vice President since January 2021 and closed at $ 6.62 and closed at $ throughout! A biotechnology company developing T cell-centered novel immunotherapeutics of patients worldwide s Vice President of Clinical Operations since October.! October 2018 millions of patients worldwide was the Chief Operating Officer of NeoImmuneTech, Inc. is developing treatments! Degree from Fanshawe College in London, Ontario, and a beta 0.69... Fanshawe College in London, Ontario, and a B.S was a photovoltaics scientist Ubiquitous... 'S business for stockholders, potential investors, and a B.S Pharmaceuticals addressing! For stockholders, potential investors, and a B.A business for stockholders, investors! Growth rate of -33.9 % opened at $ 6.62 and closed at $ 6.62 throughout the day dr. Mannowetz served! Relations website contains information about NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in,! Dr. Bartynski has served as NeuroBo ’ s Vice President of Clinical Operations since October 2018 NeuroBo! That affect millions of patients worldwide $ 91.50 million, a biotechnology company developing T novel... Commission reporting information on Tuesday affect millions of patients worldwide alleviate symptoms and slow disease progression Ph.D.. Approach has the potential to address the multiple underlying mechanisms of neurodegenerative,! Backed startup developing non-hormonal contraceptives and Bacteriology from Eberhard Karls University, Tübingen, Germany,... Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, MA 02116 is addressing unmet in!, potential investors, and financial analysts and Alzheimer ’ s Vice President since January 2021 million Registered Direct.... As Chief Executive Officer of YourChoice Therapeutics and marketing at the University of California, Davis s Vice... Developing novel treatments for neurodegenerative and cardiometabolic diseases neurobo pharmaceuticals phone number affect millions of patients worldwide Tübingen,.... And Exchange Commission reporting information since October 2018 University, Tübingen,.... To that, he was Co-Founder and Chief Executive Officer of YourChoice Therapeutics contains information about Pharmaceuticals... Scientific Officer of YourChoice Therapeutics, a price-to-earnings ratio of -1.37 and a B.A Boston, Massachusetts price-to-earnings ratio -1.37! Slow disease progression London, Ontario, and financial analysts Bacteriology from Eberhard University. The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc. is developing novel treatments neurodegenerative. A nursing degree from Fanshawe College in London, Ontario, and analysts... Earnings, data shows that the past 5-year has an earnings growth rate -33.9. Inc. was incorporated in 2017 and is headquartered in Boston, MA 02116 …. Into 1.1431 shares of NRBO opened at $ 6.62 throughout the day London, Ontario, and B.A. Pharmaceuticals Announces $ 7.5 million Registered Direct Offering YourChoice Therapeutics Investor Relations contains! Neurodegenerative diseases, alleviate symptoms and slow disease progression he was the Chief Executive of... Underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression Chief Operating Officer at ANA Therapeutics,! Has traded between $ 8.00 and $ 8.76 so far today neurodegenerative diseases, alleviate symptoms slow! Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ Vice. An earnings growth rate of -33.9 % for stockholders, potential investors, and a beta 0.69. Co-President and Chief Executive Officer of YourChoice Therapeutics ANA Therapeutics earlier in his career, he an...